Journal Article > ResearchAbstract Only
Int J Tuberc Lung Dis. 2021 September 1; Volume 25 (Issue 9); 696-700.; DOI:10.5588/ijtld.21.0125
Murphy RA, Douglas-Jones B, Mucinya G, Sunpath H, Govender T
Int J Tuberc Lung Dis. 2021 September 1; Volume 25 (Issue 9); 696-700.; DOI:10.5588/ijtld.21.0125
The wider availability of dolutegravir (DTG) containing HIV therapy for patients living with multidrug-resistant TB (MDR-TB) presents several advantages. DTG-based antiretroviral therapy (ART) has superior potency, reduces pill burden, and may reduce overall treatment-related toxicity, giving it the potential to improve outcomes in both diseases. While the uptake of DTG-based ART in programs where drug-resistant TB is treated remains unknown, there is early evidence from three programs that uptake is increasing. The use of DTG-based ART should be scaled-up, beginning with antiretroviral-naïve or virologically suppressed patients initiating MDR-TB treatment.